Publication Records

LUDWIG, H., Zdeněk ADAM, R. GREIL, E. TÓTHOVÁ, F. KEIL, N. ZOJER, J. THALER, H. GISSLINGER, M. EGYED and A. LANG. Reversal of acute renal impairment by bortezomib-doxorubicin-dexamathasone in multiple myeloma. Results from an phase II study. 2009.

SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ, T ROBAK, SH ZHUANG, JL HAROUSSEAU and R ORLOWSKI. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. United States: Wiley, 2008, vol. 112, No 7, p. 1529-1537. ISSN 0008-543X.

SLANINOVÁ, Iva, Jiří SLANINA, Iva TOMALOVÁ, Lenka BŘEZINOVÁ, Michaela BROOŠOVÁ and Ludmila KOUBÍKOVÁ. Lignans from Schisandra chinensis restore the cytotoxic action of doxorubicin in drug resistant lung cancer cells. In XIX. Biologické dny - Biologický výzkum pro lidské zdraví. 2008.

BLADÉ, J., P. SONNEVELD, JF. SAN MIGUEL, HJ. SUTHERLAND, Roman HÁJEK, A NAGLER, A SPENCER, T ROBAK, MT CIBEIRA, SH ZHUANG, JL HAROUSSEAU and RZ ORLOWSKI. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment. Clinical lymphoma & myeloma. Dallas, United States: Cancer Information Group, 2008, vol. 8, No 6, p. 352-355. ISSN 1557-9190.

ORLOWSKI, RZ., A. NAGLER, P. SONNEVELD, J. BLADÉ and Roman HÁJEK. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of clinical oncology. United States: American Society of Clinical Oncology, 2007, vol. 25, No 25, p. 3892-3901. ISSN 0732-183X.

ELBL, Lubomír, Ingrid VÁŠOVÁ, Iva TOMÁŠKOVÁ, František JEDLIČKA, Milan NAVRÁTIL, Zdeněk POSPÍŠIL and Jiří VORLÍČEK. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. Neoplasma. SLOVAKIA: VEDA, SLOVAK ACADEMY SCIENCES, 2006, vol. 53, No 2, p. 174-181. ISSN 0028-2685.

UMLAUF, Jozef, Šárka KUCHTÍČKOVÁ, B. SLANÁ and Vladimír KOTALA. APOPTOSIS OF CARDIAC MYOCYTES AND ENDOTHELIAL CELLS CONTRIBUTES TO PATHOGENESIS OF DOXORUBICIN-INDUCED CARDIOMYOPATHY IN SPONTANEOUSLY HYPERTENSIVE RATS. Biomarkers and Enviroment. Česká republika: CECHTUMA, s.r.o., 2002, vol. 5, No 1, p. 32-34. ISSN 1211-8869.

ELBL, Lubomír, Hana HRSTKOVÁ, Václav CHALOUPKA and Jan NOVOTNÝ. Echokardiografické vyhodnocení pozdních následků chemoterapie doxorubicinem v dětském věku (Echocardiographic evaluation of late side effect of doxorubicin chemotherapy in childhood). Cor et Vasa. Praha, 2002, vol. 44, No 9. ISSN 0010-9650.

UMLAUF, Jozef and Marcel HORKÝ. Molecular biology of doxorubicin-induced cardiomyopathy. Experimental and Clinical Cardiology. Canada: Pulsus Group Inc., 2002, vol. 1, No 7, p. 35-39. ISSN 1202-6626.